公开(公告)号：AT315567T

公开(公告)日：2006-02-15

申请号：AT97947567

申请日：1997-11-19

Applicant: ENDACEA INC

Inventor： NEELY CONSTANCE F

IPC: G01N33/60 ,  A01N1/02 ,  A61K31/522 ,  A61P1/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/06 ,  A61P13/00 ,  A61P15/00 ,  A61P19/02 ,  A61P37/08 ,  C07D473/06 ,  A61K31/52 ,  G01N33/06

Abstract: The invention provides compounds useful as A 1 adenosine receptor antagonists which have the formula: wherein R 1 is selected from C 1 -C 8 alkyl; R 2 is of the formula: wherein n is an integer ranging from 1 to 8; R 5 is H or CH 3 (CH 2 ) p , wherein p is an integer ranging from 1 to 7; and R 6 is H; (CH 2 ) m H; or (CH 2 ) m OH, wherein m is an integer ranging from 1 to 8; R 3 is of the formula: €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€• (CH 2 ) q C 6 H 4 €•R 7 wherein q is an integer ranging from 1 to 8; wherein R 7 is selected from H, OH, NH 2, R 9 COOH, wherein R 9 is an alkylene or alkenylene group having 1 to 8 carbon atoms, and (CH 2 ) t OH, wherein t is an integer ranging from 1 to 8; and R 4 is of the formula: wherein R 8 is selected from H, OH, NH 2 , (CH 2 ) f NH 2 wherein f is selected from 0 and an integer ranging from 1 to 8, (CH 2 ) s OH wherein s is an integer ranging from 1 to 8, and R 10 COOH wherein R 10 is an alkyxene or alkenylene group having 1 to 8 carbon atoms; and r is an integer ranging from 1 to 8.

公开(公告)号：AU5269300A

公开(公告)日：2000-12-05

申请号：AU5269300

申请日：2000-05-12

Applicant: ENDACEA INC

Inventor： NEELY CONSTANCE F

IPC: A61K9/127 ,  A61K31/00 ,  A61K31/136 ,  A61K31/522 ,  A61K31/55 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7135 ,  A61K38/06 ,  A61K38/17 ,  A61K38/19 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  A61K47/44 ,  A61K47/48 ,  A61K48/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/50 ,  G01N33/566 ,  G01N33/574 ,  G01N33/68

Abstract: Subjects at risk for developing cancer may be identified by obtaining samples of diagnostic cells from the subjects and determining a measure of cytotoxicity of the cells, the measure of cytotoxicity correlating negatively with the risk of developing cancer. The development of cancer may be prevented in subjects determined to be at risk for developing cancer by administering priming and activating agents to the subject, by increasing the expression of A 1 adenosine receptors in cells of the subject, and increasing the affinity of cells of the subject for A 1 adenosine receptor ligands. The preventative and diagnostic methods of the present invention may be carried out with kits and pharmaceutical liposomal formulations.

公开(公告)号：AU778264B2

公开(公告)日：2004-11-25

申请号：AU5269300

申请日：2000-05-12

Applicant: ENDACEA INC

Inventor： NEELY CONSTANCE F

IPC: A61K9/127 ,  A61K31/00 ,  A61K31/136 ,  A61K31/522 ,  A61K31/55 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7135 ,  A61K38/06 ,  A61K38/17 ,  A61K38/19 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  A61K47/44 ,  A61K47/48 ,  A61K48/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/50 ,  G01N33/566 ,  G01N33/574 ,  G01N33/68

Abstract: Subjects at risk for developing cancer may be identified by obtaining samples of diagnostic cells from the subjects and determining a measure of cytotoxicity of the cells, the measure of cytotoxicity correlating negatively with the risk of developing cancer. The development of cancer may be prevented in subjects determined to be at risk for developing cancer by administering priming and activating agents to the subject, by increasing the expression of A 1 adenosine receptors in cells of the subject, and increasing the affinity of cells of the subject for A 1 adenosine receptor ligands. The preventative and diagnostic methods of the present invention may be carried out with kits and pharmaceutical liposomal formulations.